Objectives: Class C b-lactamases are prevalent among Enterobacteriaceae; however, these enzymes are resistant to inactivation by commercially available b-lactamase inhibitors. In order to find novel scaffolds to inhibit class C b-lactamases, the comparative efficacy of monocyclic b-lactam antibiotics (aztreonam and the siderophore monosulfactam BAL30072), the bridged monobactam b-lactamase inhibitor BAL29880, and carbapenems (imipenem, meropenem, doripenem and ertapenem) were tested in kinetic assays against FOX-4, a plasmid-mediated class C b-lactamase (pmAmpC).
Introduction
The prevalence and dissemination of plasmid-mediated class C b-lactamases (pmAmpCs) is a critical challenge in the treatment of infections caused by Gram-negative bacteria. 1, 2 Clinically important pmAmpCs include the CMY, MIR, MOX, LAT, FOX, DHA, ACT, ACC and CFE b-lactamase families. 2 The FOX family of class C cephalosporinases is distinctly different in amino acid sequence when compared with other class C b-lactamases. 3 All eight variants of the FOX family of b-lactamases that have been described thus far show substrate specificity for cephalosporins, including cephamycins. 2,4 -9 Studies have indicated that bla FOX is widely disseminated in the USA, is present on IncA/C and Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy 2013. This work is written by US Government employees and is in the public domain in the US. J Antimicrob Chemother 2014; 69: 682 -690 doi:10.1093/jac/dkt434 Advance Access publication 13 November 2013 pMG252 plasmids, and is often associated with the presence of plasmid-mediated quinolone resistance determinants, qnr. 8,10 -19 FOX b-lactamases have also been found outside the USA -in Europe, Central and South America, and India. 4 -7,20,21 Significantly, the presence of FOX b-lactamases can complicate the laboratory detection of extended-spectrum b-lactamases by yielding falsepositive or false-negative results. 19 In this study, FOX-4 was selected from the FOX family as a model b-lactamase because the clinical impact of this class of pmAmpC is notable. bla was identified in an Escherichia coli clinical strain isolated from a patient with a urinary tract infection in Spain. 7 FOX-4 possesses broad substrate specificity for b-lactam hydrolysis, especially cephamycins, the biochemical basis of which remains to be explored. The kinetic inhibitory profiles of monocyclic b-lactams and carbapenems against FOX-4 were investigated in this analysis to determine whether these compounds have broad inhibitory profiles against plasmid-encoded cephamycinases.
To date, studies of the inhibition of class C enzymes by b-lactamase inhibitors have focused on a select or restricted number of enzymes (e.g. AmpC of E. coli, and ADC-7, CMY-2 and AmpC of Pseudomonas aeruginosa). 22 -28 These studies do not fully define the mechanistic basis of AmpC inhibition. To illustrate, Bauvois et al. 29 showed that the affinity constants of pmAmpCs were significantly different compared with chromosomal AmpCs and that enzyme production in the periplasmic space is variable. These uncertainties merit more careful study.
Class C cephalosporinases are usually resistant to the action of commercially available b-lactamase inhibitors (i.e. clavulanic acid, sulbactam and tazobactam). The search for new compounds, including b-lactamase-stable antibiotics and inhibitors of these enzymes, therefore assumes paramount importance. 30 Many experimental b-lactamase inactivators have been described and at least three are in clinical development (i.e. avibactam, MK-7655 and RPX7009). 31, 32 However, some years will pass before any reach clinical use.
As an antimicrobial agent, aztreonam effectively inhibits class C b-lactamases by acting as a poor substrate because its C 4 methyl substituent prevents rotation that would otherwise expose the ester bond of the acyl adduct to hydrolytic attack. 29, 33 The bridged monobactams were designed to exploit this principle, 34 and BAL29880, which does not have intrinsic antimicrobial properties, has been shown to be an effective class C b-lactamase inhibitor. 24, 35 The siderophore monosulfactam BAL30072 (bearing a side chain that can enhance its entry to cells through bacterial iron uptake systems) is effective against many cephalosporin-and carbapenem-resistant strains. 24, 36, 37 The potential of BAL30072 as a broad-based inhibitor of class C b-lactamases has not been fully evaluated.
Carbapenems such as imipenem were shown to act as class C b-lactamase inhibitors, 2, 24, 38, 39 and were studied as inhibitors of the P. aeruginosa and E. coli class C b-lactamases as well as of CMY-2 and ADC-7. 22 -24,40 These molecules form stable acylenzyme adducts in which the 6a-hydroxyethyl side chain is believed to force the electrophilic acyl centre to rotate away from the point of hydrolytic attack. 39 The high apparent affinity of carbapenems for class C b-lactamases makes them attractive candidates for further development as drugs with dual properties (i.e. as antibiotics and b-lactamase inhibitors). 38 
Plasmids and strains
The cloning of the bla FOX-4 gene into pGEX-6p-1 and pBGS18 was previously reported. 3 The pGEX-6p-1 clone in E. coli BL21 (DE3) was used for protein expression. The pBGS18 clone expressed in E. coli TG1 was used for antimicrobial susceptibility testing.
Protein expression and purification
The expression and purification of the FOX-4 b-lactamase was previously described. 3 
Kinetic parameters
The purified enzyme was used in all the studies reported here. Kinetic experiments were carried out with an Agilent 8453 diode array spectrophotometer at room temperature in 10 mM PBS buffer at pH 7.4. V max and K m were determined from initial steady-state velocities for NCF, D1 482 ¼17400 M 21 cm 21 . These parameters were calculated using iterative non-linear least-squares fit of the data to the Henri-Michaelis-Menten equation using Enzfitter TM (Biosoft Corporation) according to
Here, v is observed velocity, V max is maximum velocity, [S] is substrate concentration and K m is the Michaelis constant. The simplified scheme in Figure 2 depicts the interactions of FOX-4 with inhibitors chosen for this study. K i values correspond to a relative affinity or k 21 /k 1 of the inhibitor for the enzyme (for inhibitors that acylate slowly) or to the Michaelis constant or (k 21 +k 2 )/k 1 of the inhibitor for the enzyme (for inhibitors that acylate more rapidly). :
The plots were linear and provided y-intercept and slope values used for K i determination. K i was determined by dividing the value for the y-intercept by the slope of the line and then corrected by taking into account the NCF affinity (Equation 3):
Here, [S] is the concentration of NCF (200 mM) used in the assay and K m is the Michaelis constant determined for NCF (74 mM). Progress curves with a fixed concentration of enzyme and NCF, and increasing inhibitor concentration, were used to determine the k inact and K I values, as previously described. 41 k inact values indicate the number of molecules of enzyme that are inactivated per second; a higher value equates to a more rapid inactivation of the enzyme by the inhibitor. The K I value corresponds to the concentration of inhibitor required to reach 1 2 k inact . Progress curves were fit to Equation 4 to obtain k obs values using iterative non-linear least-squares fit of the data employing Origin 7.5 software.
Here, A is absorbance, v 0 (expressed in variation of absorbance per unit time) is initial velocity, v f is final velocity and t is time. k obs was plotted Papp-Wallace et al.
versus the inhibitor concentrations of the experiment and fit to determine k inact according to Equation 5 . The K I value obtained was corrected using Equation 3 .
Turnover numbers (t n ) or partition ratios (k cat /k inact ) are defined herein as the ratio of inhibitor concentration to enzyme concentration necessary to decrease the enzyme activity by 95%. t n corresponds to the number of inhibitor molecules an enzyme turns over before the enzyme is inhibited; thus, the lower the number the more effective the inhibitor for the time period measured. The t n values were determined after 15 min and 24 h of incubation with increasing concentrations of the inhibitor. Incubations were done in a final volume of 300 mL, and 25 mL of this reaction mixture was added to a 1 mL final volume to determine the residual enzyme activity using 200 mM NCF.
Ultraviolet difference (UVD) spectroscopy and formation of spectroscopic intermediates
To monitor the appearance of chromophore intermediates, UVD spectroscopy was conducted using a molar ratio of 1000 :1 (inhibitor/enzyme) from l¼200-350 nm as previously described. 42 Measurements were made every 12 s for 60 min.
Electrospray ionization mass spectrometry (ESI-MS)
b-Lactamase analysis was carried out on an Applied Biosystems (Foster City, CA, USA) QSTAR w -Elite quadrupole time-of-flight (Q-TOF) mass spectrometer equipped with a TurboIon spray TM source and an integrated syringe pump. Mass calibration was performed in the positive mode with renin solution, using the validated instrument protocol. Enzyme-toinhibitor ratios were based on the amount of inhibitor required to inactivate .95% of the enzyme after 15 min or the t n at 15 min. The reaction mixtures of protein and inhibitor were desalted using C 18 ZipTips (Millipore, Bedford, Inhibition studies with FOX-4 class C b-lactamase 685 JAC MA, USA) according to the protocol recommended by the manufacturer. The protein was eluted from the ZipTips in 50 mL of acetonitrile/H 2 O/formic acid (50:49:1) before analysis. The protein eluate was then infused into the mass spectrometer at a flow rate of 5 mL/min. Mass spectra were acquired using Analyst QS v2.0 software with 80 MCA cycles and an accumulation time of 1.5 s. The mass spectra were deconvoluted by BioAnalyst TM 2.0 software using the Bayesian protein reconstruction algorithm.
Antimicrobial susceptibility testing
Agar dilution was used to determine the MICs of ampicillin, aztreonam, BAL29880, BAL30072, doripenem, ertapenem, imipenem and meropenem alone and ampicillin in combination with aztreonam, BAL29880 and BAL30072. For combination experiments, the concentrations of BAL29880, BAL30072 and aztreonam were fixed at 4 mg/L.
Results

Inhibition kinetics
Kinetic parameters of inhibition for the monocyclic b-lactams and carbapenems are summarized in Table 1 . Aztreonam possessed the lowest K i and K I values, at 0.04+0.01 mM and 0.010+0.001 mM, respectively, while BAL29880 demonstrated the highest K i and K I values, at 9+1 mM and 41+4 mM, respectively. The inactivation efficiencies (i.e. k inact /K I ) were the lowest for BAL29880 and imipenem at 0.010+0.001 mM 21 
UVD spectroscopy
UVD spectroscopy was used to detect the presence of intermediates (chromophores) formed during the inactivation process. A clear peak in the difference spectrum of the reaction mixture of FOX-4 and BAL29880 occurred at l¼255 nm (Figure 3a) . A 0 at l ¼ 255 nm increased rapidly to a stable level (representing formation of the acyl-enzyme adduct). Surprisingly, the formation of chromophores was distinctly different when aztreonam and BAL30072 were reacted with FOX-4. The difference spectrum of these reaction mixtures showed the formation of chromophores at l ¼215 nm and l ¼ 290 nm with aztreonam, and at l¼235 nm and l¼290 nm with BAL30072 (Figure 3b and c) .
The UVD spectra revealed that the chemistry of BAL29880 upon interaction with FOX-4 is different from that of aztreonam and BAL30072, as different chromophores are formed. (Figure 4a and Table 2 ). FOX-4 inactivated by aztreonam produced the full adduct of aztreonam equivalent to D +437+5 amu, as well as another smaller adduct of D+356+5 amu (Figure 4b and Table 2 ). The smaller adduct is hypothesized to represent the complexed b-lactamase with elimination of the SO 3 22 of aztreonam. 24 Complete adducts were found for FOX-4 in combination with BAL29880 and BAL30072 (D +412+5 amu and D +519+5 amu, respectively) (Figure 4c and d, and Table 2 ).
ESI-MS
Each combination of FOX-4 with a carbapenem demonstrated the full carbapenem-complexed b-lactamase, as well as an additional peak representing the acyl -enzyme complex with elimination of the C 6 hydroxyethyl side chain of the carbapenem (Figure 5a-d and Table 2 ). 23, 24, 43, 44 For all tested combinations, FOX-4 enzyme alone (39 230 amu) was not identified, indicating complete inactivation of FOX-4. An unexpected mass of 39 560+5 amu was seen in most cases; the nature of this species remains under investigation.
Antimicrobial susceptibility assays
To determine the antibacterial properties of the compounds studied and relate these to the biochemical analyses, agar dilution MICs were determined for the monocyclic b-lactams and carbapenems, and the data are presented in Table 3 . For E. coli TG1 with pBGS18 bla FOX-4 , MICs were the lowest for BAL30072, doripenem, ertapenem, meropenem and ampicillin/aztreonam, at 0.06 mg/ L, and highest for BAL29880, at .256 mg/L.
Discussion
The clinically used b-lactamase inhibitors (clavulanic acid, sulbactam and tazobactam) have limited activity against class C b-lactamases; ampicillin and ceftazidime MICs for E. coli TG1 carrying bla FOX-4 are completely unaffected when combined with these inhibitors. 3, 30 There is therefore a growing need to identify novel compounds that are active against these enzymes. In this context, the aim of this study was to test different monocyclic b-lactams (aztreonam and a siderophore monosulfactam, BAL30072), a bridged monobactam (BAL29880) and carbapenems for their ability to inhibit the class C b-lactamase FOX-4.
Among the monocyclic b-lactams, aztreonam showed the highest inactivation efficiency (k inact /K I ¼5+1 mM 21 s 21 ), owing to a very low K I (0.01+0.001 mM), followed by BAL30072 and then BAL29880. BAL29880 inactivates FOX-4 rapidly, with a high Inhibition studies with FOX-4 class C b-lactamase 687 JAC k inact value of 0.34+0.03 s 21 ; however, BAL29880 is slow to bind and/or acylate the enzyme, as evidenced by high K i , K I and t n values at 15 min. The t n at 24 h for aztreonam and BAL29880 were both 1, which shows that recovery was not detected after 24 h of incubation and that these inhibitors are not hydrolysed by FOX-4. These data are in accordance with previous results obtained with BAL29880 as an inhibitor of CMY-2. 24 The k inact /K I values are identical for CMY-2 and FOX-4 at 0.01 mM 21 s 21 . In bacteria, BAL30072 was the most effective monocyclic b-lactam, with an MIC of 0.06 mg/L; this may be owing to the enhanced ability BAL30072 to enter cells as a result of its siderophore side chain.
These observations were anticipated, as the suspected mechanism of inactivation by aztreonam and BAL29880 depends upon restricted rotation in the acyl adduct and blockade of the trajectory of the hydrolytic water molecule. 33, 34 It has been noted that the monosulfactams form less stable adducts with class C b-lactamases, probably because of the greater flexibility of the N-O-SO 3 2 group compared with N-SO 3 2 . 45 Ertapenem was the best carbapenem inhibitor of FOX-4, with a k inact /K I value of 1.1+0.2 mM 21 s 21 , followed closely by meropenem (0.62+0.08 mM 21 s 21 ); as with aztreonam, this is mostly due to low K I values (0.09+0.02 mM and 0.13+0.01 mM, respectively). Imipenem and doripenem demonstrated higher K I values and thus were less effective inhibitors by comparison. The k inact values were similar for all the carbapenems, indicating that they inactivate FOX-4 at similar rates. In bacteria, all the carbapenems were similarly effective against E. coli TG1 pBGS18 bla FOX-4 , as evidenced by their MIC values of 0.06-0.25 mg/L. In clinical practice, the use of ertapenem is more limited than the other carbapenems because of its lack of activity against P. aeruginosa and Acinetobacter baumannii, 46, 47 Papp-Wallace et al.
Conclusions
In summary, our testing of aztreonam, new monocyclic b-lactams and carbapenems against a pmAmpC, FOX-4, offers a better understanding of their inhibitory behaviour against enzymes with a substrate preference for cephamycins. The data we report here propose a rationale to use both these classes of compounds with dual properties for the treatment of infections caused by microorganisms possessing the bla FOX-4 gene; one exception is BAL29880, which must be partnered with a b-lactam for activity. 38, 39 Further spectroscopic and structural studies are warranted to decipher the nature of the intermediates suggested by the UVD studies. The novel chromophores are suspected to occur due to differences in the chemistry of the R1 side chains, which may be important for FOX-4 inactivation by these compounds. 
